Keros Therapeutics, Inc. (KROS)Healthcare | Biotechnology | Lexington, United States | NasdaqGM
11.67 USD
-0.05
(-0.427%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 11.80 +0.13 (1.114%) ⇧ (April 17, 2026, 4:20 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:23 p.m. EDT
The technical setup is a bearish trap disguised by a strong fundamental thesis. Despite a high cash balance and improved operational cash flow, the stock has violated longer-term moving averages and is lagging revenue growth by 87%. The immediate options market is aggressively betting on a downside correction, and while the 'Strong Buy' analyst upgrade suggests a long-term turnaround, the current valuation premium and lack of consistent revenue growth make it a risky short holding. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.311322 |
| AutoETS | 0.311325 |
| MSTL | 0.313010 |
| AutoTheta | 0.380098 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 28.27 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.064 |
| Excess Kurtosis | -1.49 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.57 |
| Revenue per Share | 6.557 |
| Market Cap | 355,539,008 |
| Trailing P/E | 5.07 |
| Forward P/E | -2.31 |
| Beta | 0.99 |
| Profit Margins | 35.65% |
| Website | https://www.kerostx.com |
As of April 18, 2026, 10:23 p.m. EDT: Put buying (10.0 strike) dominates the immediate short-term upside, exceeding call volume significantly at the ATMX and ITM ranges. While there is some ATM positioning in the intermediate May expiry with a 71% dist increase noted by analysts, the immediate 9-day flow is heavily skewed bearish (OI ratio indicates more puts). The June expiry shows a divergence with massive in-the-money put OI (1.5k strikes), suggesting a price floor defense below current levels, while long-dated calls show minimal positioning. Implied volatility is relatively low across the board, indicating muted expected moves unless earnings volatility spikes.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.18391609 |
| Address1 | 1,050 Waltham Street |
| Address2 | Suite 302 |
| All Time High | 88.8 |
| All Time Low | 9.12 |
| Ask | 11.72 |
| Ask Size | 4 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 348,750 |
| Average Daily Volume3 Month | 408,551 |
| Average Volume | 408,551 |
| Average Volume10Days | 348,750 |
| Beta | 0.988 |
| Bid | 11.6 |
| Bid Size | 4 |
| Board Risk | 6 |
| Book Value | 15.51 |
| City | Lexington |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.67 |
| Current Ratio | 15.452 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 12.0 |
| Day Low | 11.565 |
| Debt To Equity | 5.57 |
| Display Name | Keros Therapeutics |
| Earnings Timestamp | 1,772,658,000 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | 72,078,000 |
| Ebitda Margins | 0.29533002 |
| Enterprise To Ebitda | -0.561 |
| Enterprise To Revenue | -0.166 |
| Enterprise Value | -40,428,388 |
| Eps Current Year | -4.67333 |
| Eps Forward | -5.05333 |
| Eps Trailing Twelve Months | 2.3 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.1071 |
| Fifty Day Average Change | -1.4370995 |
| Fifty Day Average Change Percent | -0.109642826 |
| Fifty Two Week Change Percent | -18.39161 |
| Fifty Two Week High | 22.55 |
| Fifty Two Week High Change | -10.879999 |
| Fifty Two Week High Change Percent | -0.48248336 |
| Fifty Two Week Low | 10.415 |
| Fifty Two Week Low Change | 1.2550001 |
| Fifty Two Week Low Change Percent | 0.12049929 |
| Fifty Two Week Range | 10.415 - 22.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,586,352,600,000 |
| Float Shares | 19,118,514 |
| Forward Eps | -5.05333 |
| Forward P E | -2.3093684 |
| Free Cashflow | 66,236,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 78 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.47904998 |
| Gross Profits | 116,918,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.058819998 |
| Held Percent Institutions | 1.03566 |
| Implied Shares Outstanding | 30,466,069 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. |
| Long Name | Keros Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 355,539,008 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_333195513 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 87,014,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 230,103,610 |
| Number Of Analyst Opinions | 7 |
| Open | 11.98 |
| Operating Cashflow | 107,505,000 |
| Operating Margins | -75.76623 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 617 314 6297 |
| Post Market Change | 0.13000011 |
| Post Market Change Percent | 1.1139684 |
| Post Market Price | 11.8 |
| Post Market Time | 1,776,457,212 |
| Previous Close | 11.72 |
| Price Eps Current Year | -2.4971488 |
| Price Hint | 2 |
| Price To Book | 0.7524178 |
| Price To Sales Trailing12 Months | 1.4567629 |
| Profit Margins | 0.35653 |
| Quick Ratio | 15.101 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0500002 |
| Regular Market Change Percent | -0.426623 |
| Regular Market Day High | 12.0 |
| Regular Market Day Low | 11.565 |
| Regular Market Day Range | 11.565 - 12.0 |
| Regular Market Open | 11.98 |
| Regular Market Previous Close | 11.72 |
| Regular Market Price | 11.67 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 370,525 |
| Return On Assets | 0.09247 |
| Return On Equity | 0.19896 |
| Revenue Growth | -0.873 |
| Revenue Per Share | 6.557 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 19,717,533 |
| Shares Percent Shares Out | 0.0758 |
| Shares Short | 1,494,814 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,031,197 |
| Short Name | Keros Therapeutics, Inc. |
| Short Percent Of Float | 0.2974 |
| Short Ratio | 2.62 |
| Source Interval | 15 |
| State | MA |
| Symbol | KROS |
| Target High Price | 30.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 22.57143 |
| Target Median Price | 20.0 |
| Total Cash | 287,415,008 |
| Total Cash Per Share | 14.577 |
| Total Debt | 16,883,000 |
| Total Revenue | 244,060,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.3 |
| Trailing P E | 5.073913 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.694025 |
| Two Hundred Day Average Change | -4.024025 |
| Two Hundred Day Average Change Percent | -0.2564049 |
| Type Disp | Equity |
| Volume | 370,525 |
| Website | https://www.kerostx.com |
| Zip | 2,421 |